Evaluating Albumin Utilization in a Community-Based Hospital Post-Hetastarch Food and Drug Administration (FDA) Warning

Wilbert Fuerte  
*Homestead Hospital*, wilbertf@baptisthealth.net

Frances Ordieres  
*South Miami Hospital*, FrancesO@baptisthealth.net

Judy Tseng  
*South Miami Hospital*

Follow this and additional works at: [https://scholarlycommons.baptisthealth.net/se-all-publications](https://scholarlycommons.baptisthealth.net/se-all-publications)

Part of the Pharmacoeconomics and Pharmaceutical Economics Commons, and the Pharmacy Administration, Policy and Regulation Commons

Citation

Fuerte, Wilbert; Ordieres, Frances; and Tseng, Judy, "Evaluating Albumin Utilization in a Community-Based Hospital Post-Hetastarch Food and Drug Administration (FDA) Warning" (2014). *All Publications*. 329.  
[https://scholarlycommons.baptisthealth.net/se-all-publications/329](https://scholarlycommons.baptisthealth.net/se-all-publications/329)

This Conference Poster -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrie@baptisthealth.net.
Evaluating albumin utilization in a community-based hospital post-hetastarch food and drug administration (FDA) warning
Wilbert J. Fuerte, BS, Pharm.D., Frances Ordonez, Pharm.D., Judy Tseng, Pharm.D., BCPS
South Miami Hospital, Miami, Florida

Background

- Albumin is a medication commonly used in the hospital setting.
- The use of albumin is not justified in every clinical situation due to the lack of scientific evidence and the availability of other, equally effective medications.1
- In June 2012, the FDA released a warning regarding an increase in mortality and mortality when hetastarch is used in several clinical settings.2
- Because albumin and hetastarch are colloids, overlap exists in many of the indications of these two medications. Thus, it is expected that many prescribers will use albumin in place of hetastarch in a variety of clinical scenarios. Consequently, an increase in albumin utilization and associated expenditure is expected.

Objectives

1. To identify albumin and hetastarch utilization.
2. To evaluate if albumin is used for indications consistent with the recommendations from the American Thoracic Society (ATS) guidelines for the use of Colloids and/or the University Health Consortium (UHC) guidelines for the use of albumin, non-protein colloids, and crystalloids.3
3. To determine if the new warning against the use of hetastarch has affected the prescribing pattern of albumin.
4. To complete a cost analysis on albumin misuse.

Methodology

- Single-center, Baptist Health South Florida Institutional Review Board-approved, retrospective chart review.
- Inclusion Criteria: All patients 18 years of age and older during the study period for which albumin and/or hetastarch were used.
- Exclusion criteria: Anyone younger than 18 years of age or who did not receive albumin or hetastarch during the study period.
- A list containing the medical record number of patients for which either albumin and/or hetastarch was used during September of 2012 and September of 2013 was obtained from the pharmacy department system specialist.
- Patients chart were reviewed in order to collect factors of different criteria described in the UHC and ATS guidelines for the appropriate utilization of albumin.
- Pricing was obtained from the pharmacy department buyer for cost analysis.

Data Analysis

- Descriptive statistics was completed for objectives 1, 2, and 3.
- A Cost-Utility analysis was conducted for objective 4.

Discussion

- Albumin was utilized in a variety of clinical conditions, with septic shock being the most common reason for utilization (42.5 %, N = 20).
- Based on the indications described in the UHC and ATS guidelines, albumin utilization during the time period described in this study was approximately used only 20.5 % of the time.
- Although albumin prescribing only increased by 10.3 % after the warning, the actual utilization of this medication increased by 47.4 %. On the other hand, hetastarch prescribing decreased by 63.9 %, while the actual utilization of the medication decreased by 50 %.
- Due to the significant increase in albumin utilization after the FDA warning, the total expenditure due to albumin utilization increased by 39.0 %.

Limitations

- The use of albumin was considered inappropriate only if both guidelines recommended against the use of albumin for the indication being analyzed.
- The type of surgery was not recorded unless it was a liver or cardiac surgery.
- The possibility of conditions precluding the use of normal saline were not considered for sepsis patients.
- Small sample size and study duration.

Conclusion

- Although the data provided by this audit shows that prescribers are following the FDA recommendation of minimizing the use of hetastarch, it is concerning that albumin was appropriately utilized only 20.5 % of the time. Based on these findings, there is an opportunity for improvement in educating prescribers regarding the appropriate use of albumin in order to ensure proper utilization of this medication.

References

3. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. [Internet]. 2013 [cited 2013 June 24]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm358071.htm

Disclosure

Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation:
Wilbert J. Fuerte: Nothing to disclose.
Frances Ordonez: Nothing to disclose.
Judy Tseng: Nothing to disclose.